<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Psychopharmacol Neurosci</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Psychopharmacol Neurosci</journal-id>
      <journal-title-group>
        <journal-title>Clinical Psychopharmacology and Neuroscience</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1738-1088</issn>
      <issn pub-type="epub">2093-4327</issn>
      <publisher>
        <publisher-name>Korean College of Neuropsychopharmacology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28138114</article-id>
      <article-id pub-id-type="pmc">5290718</article-id>
      <article-id pub-id-type="doi">10.9758/cpn.2017.15.1.68</article-id>
      <article-id pub-id-type="publisher-id">cpn-15-068</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Disulfiram Induced Psychosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mohapatra</surname>
            <given-names>Satyakam</given-names>
          </name>
          <xref ref-type="corresp" rid="c1-cpn-15-068"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rath</surname>
            <given-names>Nihar Ranjan</given-names>
          </name>
        </contrib>
        <aff id="af1-cpn-15-068">Mental Health Institute, S.C.B. Medical College, Cuttack, 
<country>India</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1-cpn-15-068">Address for correspondence: Satyakam Mohapatra, MD, Mental Health Institute, S.C.B. Medical College, Dock Road, Manglabag, Cuttack, Odisha 753007, India, Tel: +91-671-2441997, E-mail: <email>satyakgmu@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <volume>15</volume>
      <issue>1</issue>
      <fpage>68</fpage>
      <lpage>69</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2017, Korean College of Neuropsychopharmacology</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access">
          <license-p>This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Disulfiram is the commonly prescribed drug for the treatment of alcohol dependence. It&#x2019;s major metabolite (diethyldithiocarbamate) is an inhibitor of dopamine-betahydroxylase, an enzyme that catalyzes the metabolism of dopamine to norepinephrine resulting in psychosis. We recommend that disulfiram should be used at the lowest effective dose, possibly 250 mg daily and caution should be taken while prescribing disulfiram for patients with personal and familial antecedents of psychosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Disulfiram</kwd>
        <kwd>Psychosis</kwd>
        <kwd>Side effect</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>For the past 50 years disulfiram is the commonly prescribed drug for the treatment of alcohol dependence. Important side effects of disulfiram are hepatological, dermatological, neurological (polyneuritis, encephalopathy)<xref rid="b1-cpn-15-068" ref-type="bibr">1</xref>,<xref rid="b2-cpn-15-068" ref-type="bibr">2)</xref> and psychiatric in nature. Psychiatric manifestations include confusion, loss of memory, psychosis,<xref rid="b3-cpn-15-068" ref-type="bibr">3</xref>&#x2013;<xref rid="b6-cpn-15-068" ref-type="bibr">6)</xref> mania with psychotic symptoms.<xref rid="b7-cpn-15-068" ref-type="bibr">7</xref>,<xref rid="b8-cpn-15-068" ref-type="bibr">8)</xref> Disulfiram&#x2019;s major metabolite diethyldithiocarbamate is an inhibitor of dopamine-betahydroxylase (DBH), an enzyme that catalyzes the metabolism of dopamine (DA) to norepinephrine (NE).<xref rid="b9-cpn-15-068" ref-type="bibr">9)</xref> By inhibiting this metabolic pathway from DA to NE in the central nervous system, disulfiram results in an increase of DA concentrations in mesolimbic system resulting in psychosis. Alcoholics who developed psychotic symptoms during disulfiram treatment are found to have low levels of amine and monoamine oxidase, suggesting DBH blockage.<xref rid="b10-cpn-15-068" ref-type="bibr">10)</xref> We present a case of 32-year-old male who developed psychosis with the use of disulfiram.</p>
    </sec>
    <sec>
      <title>CASE</title>
      <p>A 32-year-old male without past of psychiatric and neurological illness reported to psychiatry outpatient department with complaint of daily alcohol intake of 250&#x2013;750 ml (40% alcohol by volume) for the last 5 years. With the informed consent of the patient, disulfiram was administered at the dosage of 250 mg twice daily for 1 month, while the patient abstained from alcohol. Then the patient presented complaint of fearfulness, suspiciousness, easy irritability, muttering to self, decreased sleep for last one month. Detailed medical evaluation revealed no significant findings. Haematological and biochemical indices were within normal limits. On mental status examination delusion of persecution and auditory hallucinations were elicited. He has family history of schizophrenia and comorbid alcohol dependence in his father. The patient has no history of any other substance abuse. The patient was hospitalised and possibility of psychosis induced by disulfiram was kept. Disulfiram was stopped. Symptoms of alcohol withdrawal and disulfiram-alcohol reactions were not observed during hospitalization. He was started on tablet lorazepam 4 mg per day. His fearfulness, suspiciousness, irritability, muttering to self and impaired sleep gradually improved over a period of 10 days. After 2 weeks he improved completely and lorazepam was stopped.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Risk factors for development of disulfiram related psychotic symptoms include past history or family history of psychosis, overly rapid increase in dosage or greater than recommended total dosage, old age, impaired liver function and concurrent dopaminergic medications or psycho-stimulant abuse.<xref rid="b5-cpn-15-068" ref-type="bibr">5</xref>,<xref rid="b11-cpn-15-068" ref-type="bibr">11)</xref> Our patient has family history of schizophrenia in his father. His psychotic symptoms improved after stoppage of disulfiram and use of lorazepam tablet only without any additional requirement of anti-psychotic treatment. These factors support the association between with disulfiram use and emergence of psychotic symptoms in our patient.</p>
      <p>The usual recommended initial dosage is 500 mg per day for the first 1 or 2 weeks, followed by a maintenance dosage of 250 mg per day.<xref rid="b12-cpn-15-068" ref-type="bibr">12)</xref> Disulfiram related psychosis usually involve either therapeutic or higher than recommended dosages.<xref rid="b13-cpn-15-068" ref-type="bibr">13)</xref> Our patient has developed psychotic symptoms with 500 mg per day of disulfiram. We recommend that disulfiram should be used at the lowest effective dose, possibly 250 mg daily. Our case highlights the relevance of a careful history of patient&#x2019;s symptoms and family history that should be performed before starting treatment with disulfiram and caution should be taken while prescribing disulfiram for patients with personal and familial antecedents of psychosis. Disulfiram-related psychiatric complications are reported to be more prevalent in eastern countries,<xref rid="b3-cpn-15-068" ref-type="bibr">3)</xref> which suggests that genetic factors may play a role in disulfiram induced psychosis.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1-cpn-15-068">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohapatra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sahoo</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rath</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Disulfiram-induced neuropathy: a case report</article-title>
          <source>Gen Hosp Psychiatry</source>
          <year>2015</year>
          <volume>37</volume>
          <fpage>97.e5</fpage>
          <lpage>e6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.genhosppsych.2014.09.015</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-cpn-15-068">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotson</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Langston</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Disulfiram-induced encephalopathy</article-title>
          <source>Arch Neurol</source>
          <year>1976</year>
          <volume>33</volume>
          <fpage>141</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="doi">10.1001/archneur.1976.00500020069012</pub-id>
          <pub-id pub-id-type="pmid">1252149</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-cpn-15-068">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murthy</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
          <article-title>Psychosis during disulfiram therapy for alcoholism</article-title>
          <source>J Indian Med Assoc</source>
          <year>1997</year>
          <volume>95</volume>
          <fpage>80</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">9212576</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-cpn-15-068">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quail</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karelse</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Disulfiram psychosis. A case report</article-title>
          <source>S Afr Med J</source>
          <year>1980</year>
          <volume>57</volume>
          <fpage>551</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="pmid">7368025</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-cpn-15-068">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rex</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>M&#xF8;ller-Madsen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Psychosis due to an overdose of disulfiram (Antabus)</article-title>
          <source>Ugeskr Laeger</source>
          <year>1986</year>
          <volume>148</volume>
          <fpage>1679</fpage>
          <lpage>1680</lpage>
          <pub-id pub-id-type="pmid">3750452</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-cpn-15-068">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krishna Murthy</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Praveenlal</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>An experience with disulfiram in the management of alcohol dependence syndrome</article-title>
          <source>Indian J Psychol Med</source>
          <year>1988</year>
          <volume>11</volume>
          <fpage>145</fpage>
          <lpage>148</lpage>
        </element-citation>
      </ref>
      <ref id="b7-cpn-15-068">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ceylan</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Turkcan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mutlu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Onal</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Manic episode with psychotic symptoms associated with high dose of disulfiram: a case report</article-title>
          <source>J Clin Psychopharmacol</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>224</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1097/01.jcp.0000264974.85205.35</pub-id>
          <pub-id pub-id-type="pmid">17414256</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-cpn-15-068">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>YC</given-names>
            </name>
          </person-group>
          <article-title>Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram</article-title>
          <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>311</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.08.035</pub-id>
          <pub-id pub-id-type="pmid">17904262</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-cpn-15-068">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murphy</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Goodwin</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Brodie</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Bunney</surname>
              <given-names>WE</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>L-dopa, dopamine, and hypomania</article-title>
          <source>Am J Psychiatry</source>
          <year>1973</year>
          <volume>130</volume>
          <fpage>79</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1176/ajp.130.1.79</pub-id>
          <pub-id pub-id-type="pmid">4682751</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-cpn-15-068">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nasrallah</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>Vulnerability to disulfiram psychosis</article-title>
          <source>West J Med</source>
          <year>1979</year>
          <volume>130</volume>
          <fpage>575</fpage>
          <lpage>577</lpage>
          <!--<pub-id pub-id-type="pmcid">1238733</pub-id>-->
          <pub-id pub-id-type="pmid">516699</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-cpn-15-068">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mackie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Cannabis toxic psychosis while on disulfiram</article-title>
          <source>Br J Psychiatry</source>
          <year>1994</year>
          <volume>164</volume>
          <fpage>421</fpage>
          <pub-id pub-id-type="doi">10.1192/bjp.164.3.421a</pub-id>
          <pub-id pub-id-type="pmid">8199803</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-cpn-15-068">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brewer</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice</article-title>
          <source>Br J Psychiatry</source>
          <year>1984</year>
          <volume>144</volume>
          <fpage>200</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="doi">10.1192/bjp.144.2.200</pub-id>
          <pub-id pub-id-type="pmid">6704608</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-cpn-15-068">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larson</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Olincy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rummans</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Morse</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review</article-title>
          <source>Alcohol Clin Exp Res</source>
          <year>1992</year>
          <volume>16</volume>
          <fpage>125</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1530-0277.1992.tb00648.x</pub-id>
          <pub-id pub-id-type="pmid">1558293</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
